Skip to main content
    E

    Equillium Inc (EQ)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.15
    -0.14 (-10.85%)

    Market Cap: $106.20M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Equillium Inc (EQ) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Equillium (EQ) trades at 29.3x sales and 2.4x book value. Its P/B of 2.4x is above its 5-year median of 1.7x. Its forward P/E is 1.5x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/E1.5x
    Price to sales29.3x
    Price to book2.4x
    PEGN/A
    As of Nov 17, 2026

    Historical Medians

    MultipleCurrent5-year median10-year median
    P/B2.4x1.7xN/A
    Medians of month-end values through Oct 2026: 60 months (5-year).

    Valuation History

    Over the 3 of the 8 year ends shown that have a P/S, its P/S ranged from 0.7x in 2024 to 2.3x in 2022.

    Year endPriceP/SP/B
    2025$1.55N/A5.0x
    2024$0.750.7x1.4x
    2023$0.720.7x1.1x
    2022$1.062.3x1.1x
    2021$3.77N/A1.7x
    2020$5.35N/A1.9x
    2019$3.38N/A1.4x
    2018$8.16N/A2.0x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About EQ

    What is EQ's forward P/E ratio?

    Equillium has a forward P/E ratio of 1.5x.

    Is EQ stock overvalued?

    GNG's valuation label for EQ is Overvalued.

    What is EQ's price to sales ratio?

    Equillium has a price to sales ratio of 29.3x.